Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,329
  • Shares Outstanding, K 70,704
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,430 K
  • EBIT $ -102 M
  • EBITDA $ -100 M
  • 60-Month Beta -0.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.88

Options Overview Details

View History
  • Implied Volatility 234.57% (+18.87%)
  • Historical Volatility 77.39%
  • IV Percentile 77%
  • IV Rank 21.43%
  • IV High 791.65% on 11/20/25
  • IV Low 82.66% on 03/25/25
  • Expected Move (DTE 28) 0.4590 (34.77%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 388
  • Volume Avg (30-Day) 234
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 27,380
  • Open Int (30-Day) 26,273
  • Expected Range 0.8610 to 1.7790

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.27
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +69.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +28.16%
on 02/04/26
1.4794 -10.77%
on 01/22/26
-0.0600 (-4.35%)
since 01/20/26
3-Month
0.8719 +51.39%
on 11/21/25
1.6600 -20.48%
on 01/15/26
+0.3200 (+32.00%)
since 11/20/25
52-Week
0.8719 +51.39%
on 11/21/25
3.7300 -64.61%
on 02/21/25
-2.3300 (-63.84%)
since 02/20/25

Most Recent Stories

More News
Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or “Company management”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.3200 (unch)
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones

Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucagon-like...

BMEA : 1.3200 (unch)
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim...

BMEA : 1.3200 (unch)
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif.,...

BMEA : 1.3200 (unch)
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.3200 (unch)
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.3200 (unch)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced...

BMEA : 1.3200 (unch)
Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.3200 (unch)
Biomea Fusion to Participate at Jefferies London Healthcare Conference

SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today...

BMEA : 1.3200 (unch)
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys...

BMEA : 1.3200 (unch)

Business Summary

Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 1.4500
2nd Resistance Point 1.4100
1st Resistance Point 1.3650
Last Price 1.3200
1st Support Level 1.2800
2nd Support Level 1.2400
3rd Support Level 1.1950

See More

52-Week High 3.7300
Fibonacci 61.8% 2.6382
Fibonacci 50% 2.3010
Fibonacci 38.2% 1.9637
Last Price 1.3200
52-Week Low 0.8719

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar